Monopar Therapeutics Inc. (NASDAQ:MNPR) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Monopar Therapeutics Inc. (NASDAQ:MNPR) has received an average rating of "Moderate Buy" from six analysts, with one hold rating and five buy ratings, indicating positive market sentiment towards the stock.
• The company's shares opened at $31.34 with a 1-year price range between $1.72 and $54.30, reflecting significant volatility in its stock performance.
• Insider trading activity showed that both the Director and CEO sold 16,800 shares each at an average price of $40.00, representing a notable decrease in their ownership stakes in the company.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) has received an average rating of "Moderate Buy" from the six ratings firms that are covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $60.00.

A number of equities research analysts recently weighed in on the stock. Wall Street Zen raised shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Chardan Capital reissued a "buy" rating and set a $60.00 price target on shares of Monopar Therapeutics in a research note on Wednesday. Finally, Cantor Fitzgerald assumed coverage on shares of Monopar Therapeutics in a research note on Monday, July 7th. They set an "overweight" rating and a $74.00 price target for the company.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, CEO Chandler Robinson sold 16,800 shares of the company's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the completion of the sale, the chief executive officer owned 73,472 shares of the company's stock, valued at approximately $2,938,880. This represents a 18.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christopher M. Starr sold 16,800 shares of the company's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the sale, the director directly owned 5,173 shares of the company's stock, valued at $206,920. The trade was a 76.46% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 42,504 shares of company stock valued at $1,700,160. Corporate insiders own 20.50% of the company's stock.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Police & Firemen s Retirement System of New Jersey acquired a new position in Monopar Therapeutics during the second quarter worth $34,000. AlphaQuest LLC bought a new stake in Monopar Therapeutics during the first quarter worth $44,000. JPMorgan Chase & Co. bought a new stake in Monopar Therapeutics during the fourth quarter worth $45,000. New York State Common Retirement Fund bought a new stake in Monopar Therapeutics during the second quarter worth $104,000. Finally, Gerber LLC bought a new stake in Monopar Therapeutics during the first quarter worth $204,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Stock Performance

Shares of NASDAQ MNPR traded up $2.68 during trading on Tuesday, reaching $36.19. The company had a trading volume of 24,794 shares, compared to its average volume of 39,715. Monopar Therapeutics has a 52 week low of $2.15 and a 52 week high of $54.30. The stock has a market cap of $221.48 million, a PE ratio of -10.87 and a beta of 1.05. The business's 50 day moving average price is $38.09 and its 200-day moving average price is $37.86.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.47) by $0.12. Equities analysts anticipate that Monopar Therapeutics will post -1.65 earnings per share for the current year.

About Monopar Therapeutics

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.